College of Medicine - Phoenix, University of Arizona, Phoenix, AZ 85004, USA.
School of Osteopathic Medicine, A.T. Still University, Mesa, AZ 85206, USA.
Discov Med. 2024 Oct;36(189):1933-1954. doi: 10.24976/Discov.Med.202436189.180.
Atopic dermatitis, psoriasis, rosacea, seborrheic dermatitis, allergic contact dermatitis, and irritant contact dermatitis comprise a large proportion of chronic inflammatory dermatoses. This paper reviews the clinical presentations, pathophysiology, and therapeutics of inflammatory dermatoses, highlighting recent drug developments such as lebrikizumab for atopic dermatitis as well as deucravacitinib and spesolimab for psoriasis. Chronic inflammatory dermatoses significantly impact patient quality of life and contribute to substantial healthcare costs. Effective management of severe cases often requires systemic therapies and biological therapies. A thorough clinical evaluation with a tailored therapeutic approach is essential for delivering optimal care to individuals with chronic inflammatory skin diseases.
特应性皮炎、银屑病、酒渣鼻、脂溢性皮炎、接触性皮炎和刺激性接触性皮炎构成了大部分慢性炎症性皮肤病。本文综述了炎症性皮肤病的临床表现、病理生理学和治疗方法，重点介绍了最近的药物开发进展，如 lebrikizumab 治疗特应性皮炎以及 deucravacitinib 和 spesolimab 治疗银屑病。慢性炎症性皮肤病严重影响患者的生活质量，并导致大量医疗保健费用。严重病例的有效管理通常需要系统治疗和生物治疗。对个体进行彻底的临床评估并采用个体化治疗方法对于提供慢性炎症性皮肤病患者的最佳护理至关重要。
